SMMT Stock Chart & Stats
$262.00
$0.00(0.00%)
At close: 4:00 PM EDT
$262.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$230.00 - $430.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$232.89B
Enterprise Value$10.67K
Total Cash (Recent Filing)$690.68M
Total Debt (Recent Filing)$20.38M
Price to Earnings (P/E)―
Beta0.07
Next Earnings
Nov 11, 2026EPS Estimate
-4.99Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.12
Shares Outstanding797,749,600
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)26.74
Price to Sales (P/S)0.00
P/FCF Ratio-54.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$494.91Price Target Upside88.90% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
EPS Forecast (FY)-20.07
Revenue Forecast (FY)$61.77M
Bulls Say, Bears Say
Bulls Say
Strong Phase III EfficacyRepeated positive Phase III outcomes and consistent overall-survival hazard ratios below 0.80 strengthen ivonescimab’s clinical credibility. This broad evidence base can support regulatory filings, physician adoption, partnership interest, and a more durable competitive position in oncology.
Advancing FDA ReviewA BLA under active FDA review creates a defined path toward potential U.S. commercialization rather than leaving the lead asset at an earlier research stage. A decision could materially expand Summit’s opportunity and validate its development strategy within the next several months.
Broad Oncology Development PlatformMultiple collaborations and tumor-specific programs diversify development beyond a single indication and provide additional opportunities to prove ivonescimab’s utility. A broader clinical footprint can increase the asset’s strategic value and create more potential routes to future approvals.
Bears Say
Pre-revenue And Large LossesSummit has not yet established recurring product revenue, so its financial profile remains dependent on advancing an uncommercialized clinical asset. Large losses limit earnings visibility and leave future financial performance highly sensitive to trial outcomes and regulatory progress.
Heavy And Rising Cash BurnHigh operating cash use across several global Phase III programs increases the resources required before potential commercialization. Rising expenses can shorten the company’s funding runway and constrain flexibility if development timelines extend or additional trials become necessary.
Regulatory And Statistical UncertaintyEven with encouraging results, approval remains contingent on the FDA’s assessment of statistically significant overall-survival evidence. Additional agency requests, delayed timing, or insufficient statistical support could postpone commercialization and reduce the expected value of the lead program.
Summit Therapeutics News
SMMT FAQ
What was Summit Therapeutics’s price range in the past 12 months?
Summit Therapeutics lowest stock price was $230.00 and its highest was $430.00 in the past 12 months.
What is Summit Therapeutics’s market cap?
Summit Therapeutics’s market cap is $232.89B.
When is Summit Therapeutics’s upcoming earnings report date?
Summit Therapeutics’s upcoming earnings report date is Nov 11, 2026 which is in 62 days.
How were Summit Therapeutics’s earnings last quarter?
Summit Therapeutics released its earnings results on Jul 23, 2026. The company reported -$4.77 earnings per share for the quarter, missing the consensus estimate of -$4.667 by -$0.102.
Is Summit Therapeutics overvalued?
According to Wall Street analysts Summit Therapeutics’s price is currently Undervalued.
Does Summit Therapeutics pay dividends?
Summit Therapeutics does not currently pay dividends.
What is Summit Therapeutics’s EPS estimate?
Summit Therapeutics’s EPS estimate is -4.99.
How many shares outstanding does Summit Therapeutics have?
Summit Therapeutics has 797,749,600 shares outstanding.
What happened to Summit Therapeutics’s price movement after its last earnings report?
Summit Therapeutics reported an EPS of -$4.77 in its last earnings report, missing expectations of -$4.667. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Summit Therapeutics?
Currently, no hedge funds are holding shares in MX:SMMT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Summit Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$494.91 (88.90% Upside)
$494.91 (88.90% Upside)
Blogger Sentiment
Bullish
MX:SMMT Sentiment 92%
Sector Average 60%
Sector Average 60%
Insider Transactions
Bought Shares
Worth $1.7B over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-6.82%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
132.13%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Summit Therapeutics
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
SMMT Company Deck
SMMT Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized substantial clinical progress for ivonescimab — multiple positive Phase III PFS readouts, overall survival hazard ratios consistently under 0.80, extensive global clinical activity, commercial exposure in China, and a strong cash balance with no debt. Key near-term catalysts include the FDA PDUFA date (Nov 14, 2026) and upcoming HARMONi-3 interim analyses. Offsetting risks include accelerating operating costs and cash burn, reliance on ATM financings, regulatory uncertainty around statistically significant OS for approval, and the statistical/operational complexity introduced by multiple interim OS looks and regional maturity differences. Overall, the positives around clinical data and pipeline breadth outweigh the financial and regulatory risks presented on the call.View all MX:SMMT earnings summariesSMMT Stock 12 Month Forecast
Average Price Target
$494.91
▲(88.90% Upside)
Technical Analysis
ImmunityBio
―
Zai Lab
―
Arcus Biosciences
―
Immunocore Holdings
―
CG Oncology, Inc.
―